8-K
filed November 15, 2022, 6:59 PM ET
ticker IDXG
CIK 0001054102
other material
confidence high
sentiment neutral
materiality 0.60
Interpace stockholders approve equity plan share increases and reverse split authorization
INTERPACE BIOSCIENCES, INC.
- Stockholders approved amendment to 2019 Equity Incentive Plan, increasing authorized shares by 1,000,000 to total 2,230,000.
- Stockholders approved amendment to Employee Stock Purchase Plan, increasing authorized shares by 1,000,000 to total 2,000,000.
- Stockholders granted board discretionary authority to effect a reverse stock split within range of 1-for-2 to 1-for-10, within one year.
- Stephen J. Sullivan elected as Class I director, receiving 8,793,313 votes for and 820,085 withhold.
- Ratification of EisnerAmper LLP as independent auditor for fiscal year ending Dec 31, 2022 approved with 11,041,434 votes for.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
INTERPACE BIOSCIENCES, INC. shareholders approved Approval of the ESPP Amendment. at the 2022-11-10 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2022-11-10
Exact text from the filing
III. Approval of the ESPP Amendment. For Against Abstain Broker Non-Votes 9,501,243 85,297 26,858 1,522,847
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
INTERPACE BIOSCIENCES, INC. shareholders approved Ratification of the appointment of EisnerAmper, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. at the 2022-11-10 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2022-11-10
Exact text from the filing
V. Ratification of the appointment of EisnerAmper, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. For Against Abstain Broker Non-Votes 11,041,434 35,207 59,604 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
INTERPACE BIOSCIENCES, INC. shareholders approved Approval of the Plan Amendment. at the 2022-11-10 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2022-11-10
Exact text from the filing
II. Approval of the Plan Amendment. For Against Abstain Broker Non-Votes 9,498,523 88,097 26,778 1,522,847
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
INTERPACE BIOSCIENCES, INC. shareholders approved Election of one Class I director to serve until the 2025 annual meeting or until such director's successor is duly elected and qualified. at the 2022-11-10 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2022-11-10
Exact text from the filing
I. Election of one Class I director to serve until the 2025 annual meeting or until such director’s successor is duly elected and qualified. Name For Withhold Broker Non-Votes Stephen J. Sullivan 8,793,313 820,085 1,522,847
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
INTERPACE BIOSCIENCES, INC. shareholders approved To grant the board of directors of the Company (the “Board”) discretionary authority to amend the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of its common stock within the range of 1-for-2 to 1-for-10 with the exact ratio, if any, to be determined by the Boar at the 2022-11-10 meeting.
- Proposal
- reverse split
- Outcome
- passed
- Meeting
- 2022-11-10
Exact text from the filing
IV. To grant the board of directors of the Company (the “Board”) discretionary authority to amend the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of its common stock within the range of 1-for-2 to 1-for-10 with the exact ratio, if any, to be determined by the Board, but not later than one year after stockholder approval thereof. For Against Abstain Broker Non-Votes 10,270,993 800,853 64,399 0
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.